A new study in ovarian cancer found that using IgA-based antibodies produced by B cells may represent new immunotherapeutic agents for tumors resistant to conventional immune checkpoint blockade, which are currently focused on T cell-centric approaches. By design, immunotherapies are designed to boost the body’s T cells to recognize and…

Population-wide screening of younger women for hereditary breast and ovarian cancer (HBOC) may be more cost-effective than broadly testing older women, according to a new study in JAMA Network Open. Women between the ages of 20 and 35, the researchers found, have more time to take action to prevent these…

Screening for cancer, and catching it in the earliest possible stages, is a proven method of increasing survival odds for this deadly disease. However, most cancer screening tests are non-existent for patients lacking access to a clinic, even the increasingly reliable genetic screens that identify patients at greatest risk. Until…

Once ovarian cancer cells slough off from their site of origin, they tend to find a new home in tissues with high fat content. Now, researchers have shown that those ovarian cancer cells use fats as an energy source. At the heart of the transition to fatty acid metabolism is…

New advances in single cell RNA sequencing technology has brought researchers from the UK closer to discovering the cellular origin of a multitude of ovarian cancer subtypes, which they hope will eventually allow for the development a screening tool and better treatment options for this silent killer of women. Ovarian…

Myriad Genetics said today that its BRACAnalysis Diagnostic System has won a third regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) that will allow physicians to determine which women with breast cancer are at risk of having Hereditary Breast and Ovarian Cancer (HBOC) syndrome—and thus eligible for…

The FDA has approved Myriad Genetics’ myChoice CDx as a companion diagnostic for Zejula (niraparib) to identify women with advanced ovarian cancer in the late-line treatment setting—an indication added by the agency to its approved uses for the poly ADP-ribose polymerase (PARP) inhibitor marketed by GlaxoSmithKline (GSK). The FDA’s approval…

The FDA has approved an expanded indication for Foundation Medicine’s FoundationOne®CDx, authorizing the test as a companion diagnostic for the AstraZeneca/Merck & Co. co-developed Lynparza (olaparib) for first line maintenance therapy in BRCA-mutated advanced ovarian cancer. FoundationOne CDx is an FDA-approved comprehensive genomic profiling (CGP) test for all solid tumors…

Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise diagnostic for suspected ovarian cancer that would eliminate the need for exploratory surgery. This could lead to a reduction in unnecessary surgery and to earlier detection…

Patients with ovarian cancer are not getting all the testing they need, according to study a recently published in Journal of Clinical Oncology. Breast and ovarian cancer testing has become more complicated over the years, and recommended for more types of patients. The question these researchers asked was “Is practice…

DNA shed by tumors into the bloodstream is starting to be used for the early detection of cancer and for monitoring how well treatment is working. Such DNA, which is called circulating tumor DNA (ctDNA), hasn’t been quite as helpful with respect to another important task—the selection of the best…

Personalized nutrition company Viome announced a new collaboration with precision health company, Helomics, to study the link between the gut microbiome and ovarian cancer. Initial collaboration will be centered on a pilot study to determine how a number of different cancer treatments affect the composition of the gut microbiome and…

Scientists at Imperial College London and the University of Melbourne have developed artificial intelligence (AI) software that they claim can more accurately predict ovarian cancer prognosis than current methods, and which can also indicate which treatments are most likely to be effective for individual patients. The software, which has been…

Sponsor: The webinar will focus on some of the current challenges facing researchers looking to improve biomarker discovery for ovarian cancer.

Myriad Genetics will apply its BRACAnalysis CDx® test as a companion diagnostic for Clovis Oncology’s approved ovarian cancer treatment Rubraca (rucaparib), the companies said today. The value and other financial terms were not disclosed for the collaboration, which is intended to fulfill a post-approval regulatory commitment by Clovis to the…